Updated

Merck beat quarterly estimates and raised its profit outlook on October 29, 2026, as sales of Keytruda, including a newer injectable form, came in stronger than expected. The immunotherapy drug's performance was the main driver of the quarter, according to the headline coverage. Further details on the size of the beat were not included in the available reporting.